McCarthy Patrick, Pathakamuri Joseph A, Kuebler Daniel, Neves Jocelyn, Krohn Madison, Rohall Michael, Archibeque Isaac, Giese Heidi, Werner Martina, Daviso Eugenio, Thomann Ulrich
Covaris, LLC., Woburn, MA 01801, USA.
Department of Biology, Franciscan University, Steubenville, OH 43952, USA.
Vaccines (Basel). 2022 Oct 20;10(10):1760. doi: 10.3390/vaccines10101760.
The COVID-19 pandemic has revealed a crucial need for rapid, straightforward collection and testing of biological samples. Serological antibody assays can analyze patient blood samples to confirm immune response following mRNA vaccine administration or to verify past exposure to the SARS-CoV-2 virus. While blood tests provide vital information for clinical analysis and epidemiology, sample collection is not trivial; this process requires a visit to the doctor's office, a professionally trained phlebotomist to draw several milliliters of blood, processing to yield plasma or serum, and necessitates appropriate cold chain storage to preserve the specimen. A novel whole blood collection kit (truCOLLECT) allows for a lancet-based, decentralized capillary blood collection of metered low volumes and eliminates the need for refrigerated transport and storage through the process of active desiccation. Anti-SARS-CoV-2 spike (total and neutralizing) and nucleocapsid protein antibody titers in plasma samples obtained via venipuncture were compared to antibodies extracted from desiccated whole blood using Adaptive Focused Acoustics (AFA). Paired plasma versus desiccated blood extracts yields Pearson correlation coefficients of 0.98; 95% CI [0.96, 0.99] for anti-SARS-CoV-2 spike protein antibodies, 0.97; 95% CI [0.95, 0.99] for neutralizing antibodies, and 0.97; 95% CI [0.94, 0.99] for anti-SARS-CoV-2 nucleocapsid protein antibodies. These data suggest that serology testing using desiccated and stabilized whole blood samples can be a convenient and cost-effective alternative to phlebotomy.
新冠疫情揭示了对生物样本进行快速、简便采集和检测的迫切需求。血清学抗体检测可分析患者血液样本,以确认接种mRNA疫苗后的免疫反应或验证过去是否接触过SARS-CoV-2病毒。虽然血液检测为临床分析和流行病学提供了重要信息,但样本采集并非易事;这个过程需要前往医生办公室,由专业培训的采血人员抽取几毫升血液,进行处理以获得血浆或血清,并且需要适当的冷链储存来保存样本。一种新型全血采集试剂盒(truCOLLECT)允许通过基于柳叶刀的方式,在分散地点采集定量的少量毛细血管血,并且通过主动干燥过程消除了冷藏运输和储存的需求。将通过静脉穿刺获得的血浆样本中的抗SARS-CoV-2刺突蛋白(总抗体和中和抗体)和核衣壳蛋白抗体滴度与使用自适应聚焦声学(AFA)从干燥全血中提取的抗体进行比较。配对的血浆与干燥血提取物的抗SARS-CoV-2刺突蛋白抗体的皮尔逊相关系数为0.98;95%置信区间[0.96, 0.99],中和抗体为0.97;95%置信区间[0.95, 0.99],抗SARS-CoV-2核衣壳蛋白抗体为0.97;95%置信区间[0.94, 0.99]。这些数据表明,使用干燥和稳定的全血样本进行血清学检测可以成为静脉穿刺采血的一种方便且经济高效的替代方法。